Clinical Trial – Suprasorb® C Collagen Wound Dressing – Venous Ulcers

Suprasorb® C collagen wound dressing is a certified medical device (manufacturer: Lohmann & Rauscher International GmbH & Co. KG). The product has been marketed in the EU since 1983 as Opragen® (medicinal product), since 1995 as the medical device Opraskin® and since 2001 under the name Suprasorb C (medical device).

Suprasorb® C is intended to be used as a wound dressing for the support of wound healing or wound area reduction. Participating Centers: 40 study nurses will participate to the PMCF Study Duration: 24 months Cohort size: 110 patients Follow-up: 8 weeks

Study Type  : Observational
Estimated Enrollment  : 110 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Post-Market Clinical-Follow-Up Study of Suprasorb® C Collagen Wound Dressing
Actual Study Start Date  : January 24, 2018
Estimated Primary Completion Date  : January 2020
Estimated Study Completion Date  : March 2020
Contacts
Contact: Helene VELASQUEZ GIRON (+33) 437 451 721 hvg@rcts.fr
Contact: Celine Fernandez (+33) 437 451 720 cfe@rcts.fr

Locations

France
RCTs Recruiting
Lyon, France, 69002
Contact: Helene VELASQUEZ GIRON    (+33) 437 451 721    hvg@rcts.fr
Contact: Celine Fernandez    (+33) 437 451 720    cfe@rcts.fr

 

ClinicalTrials.gov Identifier: NCT03444597
* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.